Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
AstraZeneca
Baxter
Harvard Business School
McKinsey

Last Updated: October 1, 2022

TOLECTIN DS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Tolectin Ds patents expire, and what generic alternatives are available?

Tolectin Ds is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.

The generic ingredient in TOLECTIN DS is tolmetin sodium. There are twelve drug master file entries for this compound. Additional details are available on the tolmetin sodium profile page.

US Patents and Regulatory Information for TOLECTIN DS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ortho Mcneil Janssen TOLECTIN DS tolmetin sodium CAPSULE;ORAL 018084-001 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TOLECTIN DS

See the table below for patents covering TOLECTIN DS around the world.

Country Patent Number Title Estimated Expiration
Austria 313268 See Plans and Pricing
Switzerland 547279 VERFAHREN ZUR HERSTELLUNG VON 5-AROYLPYRROL-DERIVATEN UND DEREN VERWENDUNG. See Plans and Pricing
Spain 416015 See Plans and Pricing
Spain 416016 See Plans and Pricing
South Africa 7100470 See Plans and Pricing
Canada 924728 PROCESS FOR PREPARING AROYL-SUBSTITUTED PYRROLES AND PRODUCT PREPARED THEREBY See Plans and Pricing
Japan S582936 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Colorcon
Boehringer Ingelheim
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.